The intracranial efficacy of targeted agents such as EGFR-TKIs or ALK inhibitors has been shown, justifying their use as first-line treatment, in combination with or without cranial RT, in case of brain-metastatic NSCLC with EGFR mutation or ALK rearrangement (10–12). The gene discussed is ALK; the disease is non-small cell lung carcinoma.